Arvinas, Inc. (ARVN)

NASDAQ: ARVN · Real-Time Price · USD
7.37
-0.02 (-0.27%)
At close: Jun 16, 2025, 4:00 PM
7.50
+0.13 (1.76%)
Pre-market: Jun 17, 2025, 4:00 AM EDT
-0.27%
Market Cap 537.95M
Revenue (ttm) 426.90M
Net Income (ttm) -46.60M
Shares Out 72.99M
EPS (ttm) -0.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,328,260
Open 7.37
Previous Close 7.39
Day's Range 7.12 - 7.40
52-Week Range 5.90 - 34.11
Beta 2.20
Analysts Buy
Price Target 20.53 (+178.56%)
Earnings Date Jul 29, 2025

About ARVN

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 27, 2018
Employees 430
Stock Exchange NASDAQ
Ticker Symbol ARVN
Full Company Profile

Financial Performance

In 2024, Arvinas's revenue was $263.40 million, an increase of 235.54% compared to the previous year's $78.50 million. Losses were -$198.90 million, -45.85% less than in 2023.

Financial Statements

Analyst Forecast

According to 21 analysts, the average rating for ARVN stock is "Buy." The 12-month stock price forecast is $20.53, which is an increase of 178.56% from the latest price.

Price Target
$20.53
(178.56% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

– ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (also known as AITL) and transformed follicular lymphoma –

3 days ago - GlobeNewsWire

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published...

10 days ago - GlobeNewsWire

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting

– Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (AIT...

11 days ago - GlobeNewsWire

Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression

An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to AstraZeneca's Faslodex in patients with a specific gene mutation, according t...

Other symbols: PFE
16 days ago - Reuters

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

NEW HAVEN, Conn. and NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 VERITAC-2 clinical trial (NCT...

16 days ago - GlobeNewsWire

Arvinas to Present at Jefferies Global Healthcare Conference

NEW HAVEN, Conn., May 30, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, t...

17 days ago - GlobeNewsWire

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Shareholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN)...

4 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Shareholders to Connect

NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN)...

4 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Shareholders to Reach Out

NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN)...

4 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Shareholders to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN)...

4 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Investors to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN)...

5 weeks ago - Accesswire

Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / May 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN)...

5 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Investors to Connect

NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN)....

5 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Stockholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN)....

5 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Investors to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN)....

5 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Investors to Reach Out

NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN)....

5 weeks ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Stockholders to Reach Out

NEW YORK, NY / ACCESS Newswire / May 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN)....

6 weeks ago - Accesswire

Arvinas: Yet Another Biotech Trading Below Net Cash, But It's Only A Mild Bull Case

I favor biotech stocks trading below cash value after setbacks; Arvinas (ARVN) fits this description, dropping 25% on Thursday after ending two Phase 3 trials. ARVN's net cash per share is over $12, p...

6 weeks ago - Seeking Alpha

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Stockholders to Connect

NEW YORK, NY / ACCESS Newswire / May 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN)....

6 weeks ago - Accesswire

Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / May 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN)....

6 weeks ago - Accesswire

Arvinas, Inc. (ARVN) Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation

BOSTON, MA / ACCESS Newswire / May 2, 2025 / Block & Leviton is investigating Arvinas, Inc. (Nasdaq:ARVN) for potential securities law violations. Investors who have lost money in their Arvinas, Inc. ...

6 weeks ago - Accesswire

Arvinas, Inc. (ARVN) Q1 2025 Earnings Call Transcript

Arvinas, Inc. (NASDAQ:ARVN) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Jeff Boyle - Vice President of Investor Relations John Houston - President and Chief Executive...

6 weeks ago - Seeking Alpha

Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update

– Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first-in-human data for the Company's first neuroscience program with ARV-102 ...

6 weeks ago - GlobeNewsWire

Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation,...

7 weeks ago - GlobeNewsWire

Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting

– ARV-393 demonstrated strong synergistic antitumor activity, including complete regressions, in combination with standard-of-care chemotherapy, biologics, and select investigational oral small molecu...

7 weeks ago - GlobeNewsWire